Lixte Biotechnology

LIXTE's Cancer Drug LB-100 Metabolism Pathway Discovered, Opening New Biomarker Strategy

2 months ago

• Scientists at the Netherlands Cancer Institute have identified an enzyme that converts LIXTE's lead compound LB-100 into its active form endothall, potentially serving as a biomarker for patient response prediction. • Researchers from BioPharmaWorks LLC demonstrated that while LB-100 can spontaneously convert to endothall through hydrolysis, this process is slow under physiological conditions, highlighting the importance of the enzymatic pathway. • The findings, published in BioXriv and International Journal of Pharmaceutics, will help optimize patient selection for ongoing clinical trials of LB-100 in ovarian and colorectal cancers.

Northwestern's Lurie Cancer Center Joins Clinical Trial Testing LIXTE's LB-100 Plus Dostarlimab for Ovarian Clear Cell Cancer

3 months ago

• Northwestern University's Lurie Cancer Center has been added as the second site in LIXTE Biotechnology's clinical trial combining LB-100 with GSK's dostarlimab for ovarian clear cell cancer treatment. • The first patient has been successfully dosed at Lurie Cancer Center under the leadership of Dr. Emily M. Hinchcliff, marking an important expansion of the study initially launched at MD Anderson Cancer Center. • The trial aims to evaluate whether LIXTE's proprietary PP2A inhibitor LB-100 can enhance immunotherapy effectiveness in treating ovarian clear cell carcinoma, addressing a significant unmet medical need.

Lixte Biotechnology Amends Collaboration Agreement for LB-100 Cancer Drug Development

6 months ago

• Lixte Biotechnology Holdings amended its collaboration with the Netherlands Cancer Institute and Oncode Institute, focusing on LB-100 in cancer treatment. • The amendment temporarily pauses study activities until a Phase 1b trial combining LB-100 with a WEE1 inhibitor for metastatic colorectal cancer begins. • The collaboration will resume upon the first patient being dosed, with a reduced annual budget of €100,000 for one year. • The aim is to analyze translational data from patient samples in clinical trials to enhance understanding of LB-100's effects.

Lixte Biotechnology Receives Nasdaq Extension and Advances LB-100 Clinical Trial

7 months ago

• Lixte Biotechnology secured a Nasdaq extension until February 18, 2025, to meet the minimum stockholders' equity requirement of $2.5 million. • The company plans to regain compliance through registered equity offerings, supported by a recent $4 million capital-raising initiative. • Lixte's cancer drug, LB-100, will be evaluated in a clinical trial at the Netherlands Cancer Institute for metastatic colon cancer in combination with atezolizumab. • Recent financial data indicates Lixte holds more cash than debt, but profitability remains a challenge, underscoring the urgency of equity-raising efforts.

Lixte Biotechnology Faces Nasdaq Delisting Over Equity Shortfall, Plans Compliance Measures

9 months ago

• Lixte Biotechnology received a Nasdaq notice for failing to meet the minimum stockholders' equity requirement of $2.5 million. • The company intends to submit a plan within 45 days to regain compliance and potentially receive a 180-day extension. • Lixte is conducting a clinical trial with the Netherlands Cancer Institute, testing LB-100 with Roche's atezolizumab for metastatic colon cancer. • Recent changes in director compensation policy shift from cash payments to equity-based remuneration to preserve cash.

Paradoxical Intervention: A Novel Strategy to Overload Cancer Cells

9 months ago

• Researchers are initiating a clinical trial using a 'paradoxical intervention' strategy to treat advanced colorectal cancer by overstimulating oncogenic signaling. • The approach involves LB-100, a PP2A inhibitor, to stress cancer cells, followed by adavosertib, a WEE1 inhibitor, to prevent DNA damage repair. • Preclinical studies in mice showed that this drug combination effectively prevented tumor growth by forcing cancer cells to behave like healthy cells to survive. • This innovative method may lead to new cancer therapies by targeting the fundamental differences between cancer and normal cells, potentially reducing toxic side effects.

Lixte Biotechnology and Netherlands Cancer Institute Partner to Trial LB-100 in Metastatic Colon Cancer

a year ago

• Lixte Biotechnology partners with the Netherlands Cancer Institute to evaluate LB-100 in metastatic colon cancer patients. • The clinical trial will combine LB-100 with atezolizumab, a PD-L1 inhibitor, to enhance the immune response against cancer cells. • Lixte will supply LB-100, while Roche will provide atezolizumab and fund the trial, with no clinical costs for Lixte. • The trial includes a dose escalation phase followed by clinical activity and safety assessment in up to 37 patients over 24 months.

Lixte Biotechnology's LB-100 Shows Promise in Multiple Cancer Indications Through Novel PP2A Inhibition

a year ago

• Lixte Biotechnology is advancing LB-100, a first-in-class protein phosphatase 2A (PP2A) inhibitor, for multiple cancer indications including soft tissue sarcoma and glioblastoma multiforme. • The drug candidate, administered both intravenously and orally, is designed to work synergistically with standard cancer treatments including chemotherapy, radiation, and immune checkpoint blockers. • LB-100, a synthetic derivative of cantharidin, demonstrates significant anti-cancer activity with minimal toxicity across various solid tumors and hematological malignancies.